Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15751022 | 0.88 | CHRM1 (0.52) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL15751056 | 0.84 | CHRM1 (0.54) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL2554935 | 0.81 | — | — | |
| SCHEMBL32679893 | 0.80 | CHRM1 (0.44) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL10919497 | 0.78 | CHRM1 (0.43) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL19812464 | 0.78 | CHRM1 (0.52) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL28716471 | 0.76 | — | — | |
| SCHEMBL9068438 | 0.74 | CA2 (0.52) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL22689615 | 0.74 | CHRM1 (0.48) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL6517896 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3851126-A1 | MAYTANSINOID-CELL-BINDING AGENT CONJUGATES | ImmunoGen, Inc. (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-3524611-B1 | IMPROVED CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | IMMUNOGEN INC (US) | 2020-12-30 | — | — | EP | disclosed |
| EP-3524611-A1 | IMPROVED CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | ImmunoGen, Inc. (US) | 2019-08-14 | — | — | EP | disclosed |
| EP-3380525-A1 | PHARMACEUTICAL FORMULATIONS AND METHODS OF USE THEREOF | Immunogen, Inc. (US) | 2018-10-03 | — | — | EP | disclosed |
| US-20180043013-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS (DM4) | IMMUNOGEN, INC. | 2018-02-15 | — | — | US | disclosed |
| WO-2017091745-A1 | PHARMACEUTICAL FORMULATIONS AND METHODS OF USE THEREOF | IMMUNOGEN, INC. (US) | 2017-06-01 | — | — | WO | disclosed |
| EP-3031810-A1 | IMPROVED CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | ImmunoGen, Inc. (US) | 2016-06-15 | — | — | EP | disclosed |
| EP-1651162-B1 | IMPROVED CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | IMMUNOGEN INC (US) | 2015-10-21 | — | — | EP | disclosed |
| US-20150071949-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS (DM4) | IMMUNOGEN, INC. | 2015-03-12 | — | — | US | disclosed |
| US-8841425-B2 | Cytotoxic agents comprising new maytansinoids | IMMUNOGEN, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20070270585-A1 | Maytansinoid intermediates: N-alkyl- or aryldithioalkanoylalanines and N-alkanoyl- or aroylthioalkanoylalanines, e.g., N-methyl-N-(4-methyl-4-methyldithio-1-oxopentyl)-alanine; optical isomers and racemic mixtures; preparations from isobutylene sulfide and acetonitrile, methyl methanethiosulfonate, etc. | IMMUNOGEN, INC. (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070264266-A1 | Maytansine derivatives having a sterically hindered thiol or disulfide groups, capable of conjugating to cell-binding agents, to form drugs having improved therapeutic efficacy in animal tumor models; antitumor agents | IMMUNOGEN INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-7276497-B2 | For therapy of tumors | IMMUNOGEN INC. | 2007-10-02 | — | — | US | disclosed |
| EP-1651162-A2 | IMPROVED CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | Immunogen, Inc. (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2004103272-A2 | IMPROVED CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | IMMUNOGEN, INC. (US) | 2004-12-02 | — | — | WO | disclosed |
| US-20040235840-A1 | For therapy of tumors | IMMUNOGEN, INC. | 2004-11-25 | — | — | US | disclosed |
| EP-0234944-B1 | INSECTICIDAL N'-SUBSTITUTED-N-ACYL-N'-ALKYLCARBONYLHYDRAZINES | ROHM AND HAAS COMPANY (US) | 1991-04-10 | — | — | EP | disclosed |
| EP-0232075-B1 | INSECTICIDAL N'-SUBSTITUTED-N-ALKYLCARBONYL-N'-ACYL HYDRAZINES | ROHM AND HAAS COMPANY (US) | 1991-03-13 | — | — | EP | disclosed |
| EP-0234944-A1 | Insecticidal N'-substituted-N-acyl-N'-alkylcarbonylhydrazines | ROHM AND HAAS COMPANY (US) | 1987-09-02 | — | — | EP | disclosed |
| EP-0232075-A1 | Insecticidal N'-substituted-N-alkylcarbonyl-N'-acyl hydrazines | ROHM AND HAAS COMPANY (US) | 1987-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070264266-A1 | Maytansine derivatives having a sterically hindered thiol or disulfide groups, capable of conjugating to cell-binding agents, to form drugs having improved therapeutic efficacy in animal tumor models; antitumor agents | SPR, SDAD1, ARRB1 | CHRM1 3086/4885AKR1A1 572/4885CHRM3 3143/4885 |
| US-20070270585-A1 | Maytansinoid intermediates: N-alkyl- or aryldithioalkanoylalanines and N-alkanoyl- or aroylthioalkanoylalanines, e.g., N-methyl-N-(4-methyl-4-methyldithio-1-oxopentyl)-alanine; optical isomers and racemic mixtures; preparations from isobutylene sulfide and acetonitrile, methyl methanethiosulfonate, etc. | AASDHPPT, AADAT, SLC6A15 | CHRM1 816/4885AKR1A1 384/4885CHRM3 1240/4885 |
| US-20040235840-A1 | For therapy of tumors | HCCS, SPR, PAICS | CHRM1 4357/4885AKR1A1 1229/4885CHRM3 3816/4885 |
| US-20180043013-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS (DM4) | PDIA4, TPD52L2, ANXA4 | CHRM1 2429/4885AKR1A1 1056/4885CHRM3 2781/4885 |
| US-20150071949-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS (DM4) | PDIA4, TPD52L2, ANXA4 | CHRM1 2429/4885AKR1A1 1056/4885CHRM3 2781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.